Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

被引：0
|
作者：
Ghader Mohammadnezhad
Behniya Azadmehr
Mehdi Mirheidari
Nazila Yousefi
机构：
[1] Shahid Beheshti University of Medical Sciences,Student Research Committee, School of Pharmacy
[2] Shahid Beheshti University of Medical Sciences,Department of Pharmacoeconomics and Pharma Management, School of Pharmacy
来源：
Cost Effectiveness and Resource Allocation | / 20卷
关键词：
Dapagliflozin; SGLT-2 inhibitors; Economic evaluation; Cost-effectiveness analysis; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [32] Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis ofDAPA-HF
    McEwan, Phil
    Darlington, Oliver
    McMurray, John J. V.
    Jhund, Pardeep S.
    Docherty, Kieran F.
    Boehm, Michael
    Petrie, Mark C.
    Bergenheim, Klas
    Qin, Lei
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (11) : 2147 - 2156
  • [33] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
    Rane, A.
    Nechi, R. N.
    Imam, M.
    Zoni, C. R.
    Ndikumukiza, C.
    Karaye, I
    Yunusa, I
    Alanazi, A.
    VALUE IN HEALTH, 2023, 26 (06) : S99 - S99
  • [34] Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
    Krittayaphong, Rungroj
    Yadee, Jirawit
    Permsuwan, Unchalee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 767 - 777
  • [35] Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
    Tsutsui, Hiroyuki
    Sakamaki, Hiroyuki
    Momomura, Shin-ichi
    Sakata, Yasushi
    Kotobuki, Yutaro
    Linden, Stephan
    Idehara, Koki
    Nitta, Daisuke
    ESC HEART FAILURE, 2024, 11 (01): : 261 - 270
  • [36] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION IN SPAIN
    Fernandez de Bobadilla, J.
    Gonzalez Fernandez, O.
    Lopez de Sa, E.
    Lopez-Sendon, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A486
  • [37] Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis
    Rane, Amey
    Nechi, Regina Nwamaka
    Imam, Maryam
    Zoni, Cesar Rodrigo
    Ndikumukiza, Cyrille
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    Alanzi, Abdullah
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (09): : 1045 - 1053
  • [38] SIMPLE APPROACH FOR DEVELOPING PARAMETRIC SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS (CEA): CASE STUDY OF HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)
    Aggarwal, S.
    Kumar, S.
    Bela, A.
    Topaloglu, O.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S96
  • [39] Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Arevalo-Lorido, Jose Carlos
    Conde-Martel, Alicia
    Salamanca-Bautista, Prado
    Manzano-Espinosa, Luis
    Formiga, Francesc
    Diez-Manglano, Jesus
    Cepeda, Jose Maria
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    FUTURE CARDIOLOGY, 2023, 19 (06) : 343 - 351
  • [40] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
12345